welcomes you to the new, improved website!A retrospective analysis of SBRT in 13 institutions over a 10 year interval was conducted on outcomes in 582 pts with Stage I NSCLC. At 3 years, freedom from local recurrence was 80% and overall survival was 47%. The biological dose was the most important determinant of outcomes. With higher effective dosing, freedom from local recurrence was 92% and overall survival was 62%.
Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non-Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis
Submitted by: Erica Curcio
Source: Journal of Thoracic Oncology
Keywords:
Author(s): Guckenberger, Matthias; Allgäuer, Michael; Appold, Steffen; Dieckmann, Karin Ernst, Iris; Ganswindt, Ute; Holy, Richard; Nestle, Ursula; Nevinny-Stickel, Meinhard; Semrau, Sabine; Sterzing, Florian; Wittig, Andrea; Andratschke, Nicolaus